EKF Diagnostics Holdings plc (LON:EKF - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 23.79 ($0.32) and traded as high as GBX 25.90 ($0.35). EKF Diagnostics shares last traded at GBX 25 ($0.34), with a volume of 261 shares traded.
EKF Diagnostics Stock Up 1.6%
The company has a market capitalization of £115.56 million, a price-to-earnings ratio of 24.20 and a beta of 0.57. The company has a quick ratio of 1.77, a current ratio of 4.60 and a debt-to-equity ratio of 0.34. The business has a 50-day moving average price of GBX 22.67 and a 200-day moving average price of GBX 23.80.
EKF Diagnostics (LON:EKF - Get Free Report) last issued its quarterly earnings results on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) earnings per share for the quarter. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%. As a group, equities analysts anticipate that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current fiscal year.
Insider Transactions at EKF Diagnostics
In other news, insider Gavin T. Jones bought 50,000 shares of the business's stock in a transaction on Tuesday, March 25th. The shares were bought at an average cost of GBX 22 ($0.30) per share, with a total value of £11,000 ($14,907.17). 5.24% of the stock is currently owned by insiders.
About EKF Diagnostics
(
Get Free Report)
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Further Reading
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
